Europe medical device industry top deal activity in March 2022

The European medical device industry saw a 7.89% increase in activity in March 2022, compared to the average of the last 12 months, led by Angelus Sano Fund, Segulah Medical Acceleration and the capital agreement- Waha Capital’s $49 million investment with Signifier Medical Technology, according to GlobalData’s deal database.

  • Embed this graphic

    Embed this graphic in your website

    Copy and paste the image source into your website to view the graphic.

A total of 41 medical device industry deals worth $251 million were announced for the region in March 2022, compared to a 12-month average of 38 deals.

Of all deal types, venture capital funding saw the most activity in March 2022 with 20 deals, accounting for a 48.8% share for the region.

In second place were mergers and acquisitions with 16 deals, followed by private equity deals with five deals, capturing a 39.02% and 12.2% share of overall deal activity for the month, respectively.

In terms of deal value, private equity was the leading category for the European medical device industry at $106.62 million, while venture finance and mergers and acquisitions totaled $84.87 million, respectively. and $59.5 million.

Medical Device Industry Deals in Europe March 2022: Top Deals

The top five medical device deals accounted for 60.9% of the overall value in March 2022.

The combined value of the top five medical device deals was $152.92 million, compared to the aggregate value of $251 million recorded for the month.

The top five medical device industry deals of March 2022 tracked by GlobalData were:

1) Angelus Sano Fund, Segulah Medical Acceleration and Waha Capital $49 million private equity deal with Signifier Medical Technology

2) The $36.42 million private equity investment of ITM Isotopen Technologien Munchen by the Aboriginal Critical Infrastructure Fund Canada (ICIF) and Portland Investment Counsel

3) $24.35 million SourceBio International acquisition agreement with LDPath

4) The acquisition of BioClue and BioStrand for $21.94 million by BioKey and ImmunoPrecise Netherlands

5) Heights Capital Ireland $21.2m private equity deal with Renalytix AI

Related companies

Verdict Agreement Analysis Methodology

This analysis only considers announced and concluded transactions from GlobalData’s financial transactions database and excludes all completed and assumed transactions. The country and industry are defined based on the target company’s head office and dominant industry. The term “procurement” refers to both completed transactions and those in the process of being tendered.

GlobalData tracks real-time data on all M&A, private equity/venture capital, and asset transaction activity globally from thousands of company websites and other trusted sources.

More in-depth reports and analysis on all reported transactions are available to subscribers at GlobalData’s job database.

Mary I. Bruner